Aptose Biosciences Inc. (TSX: APS and OTC: APTOF) has announced that its shareholders have approved the acquisition by Hanmi Pharmaceutical in a 'Go Private' transaction. This decision was made during a special shareholders meeting held on March 31, 2026. The acquisition will allow Aptose to continue and expand the development of its TUS+VEN+AZA triplet therapy, which has shown promising results in treating newly diagnosed acute myeloid leukemia (AML) patients. The company reported a net loss of $25.5 million for the year ended December 31, 2025, slightly up from a loss of $25.4 million in 2024. Despite the losses, the approval of the acquisition is seen as a significant step forward for Aptose, as it secures financial backing from Hanmi, which has provided over $41 million in support over the past two years. The arrangement includes a cash payment of C$2.41 per common share, representing a 28% premium over the company's 30-day volume-weighted average price. The court has also granted final approval for the plan of arrangement, with expectations for completion by the end of April 2026, pending regulatory approvals. This acquisition is expected to enhance Aptose's operational capabilities and strategic outlook in the oncology sector.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.